Published in Comput Programs Biomed on June 01, 1983
Pharmacokinetics and bactericidal rates of daptomycin and vancomycin in intravenous drug abusers being treated for gram-positive endocarditis and bacteremia. Antimicrob Agents Chemother (1992) 2.57
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res (2007) 2.50
Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma. Clin Cancer Res (2009) 1.92
Efficacy and safety of disodium ascorbyl phytostanol phosphates in men with moderate dyslipidemia. Eur J Clin Pharmacol (2008) 1.43
Pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-deoxy-2',3'-didehydrothymidine in rhesus monkeys. Antimicrob Agents Chemother (1990) 1.38
Phase I pharmacokinetic and pharmacodynamic study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin, an inhibitor of heat-shock protein 90, in patients with advanced solid tumors. J Clin Oncol (2010) 1.38
Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice. Cancer Chemother Pharmacol (2008) 1.38
Vancomycin pharmacokinetics in burn patients and intravenous drug abusers. Antimicrob Agents Chemother (1990) 1.32
Pharmacokinetics and pharmacodynamic modeling of direct suppression effects of methylprednisolone on serum cortisol and blood histamine in human subjects. Clin Pharmacol Ther (1989) 1.32
Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections. Antimicrob Agents Chemother (1996) 1.29
Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections. Antimicrob Agents Chemother (1996) 1.29
Differing effects of combination chemotherapy with meropenem and tobramycin on cell kill and suppression of resistance of wild-type Pseudomonas aeruginosa PAO1 and its isogenic MexAB efflux pump-overexpressed mutant. Antimicrob Agents Chemother (2009) 1.26
Pharmacokinetics and metabolism of racemic 2',3'-dideoxy-5-fluoro-3'-thiacytidine in rhesus monkeys. Antimicrob Agents Chemother (1992) 1.20
Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. J Clin Oncol (2010) 1.15
Pharmacokinetics of aztreonam in patients with gram-negative infections. Antimicrob Agents Chemother (1985) 1.15
Pharmacodynamics of vancomycin alone and in combination with gentamicin at various dosing intervals against methicillin-resistant Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model. Antimicrob Agents Chemother (1997) 1.14
Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers. Antimicrob Agents Chemother (1998) 1.12
A phase 1 dose-escalation study of irinotecan in combination with 17-allylamino-17-demethoxygeldanamycin in patients with solid tumors. Clin Cancer Res (2008) 1.12
In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of 10074-G5, a novel small-molecule inhibitor of c-Myc/Max dimerization. J Pharmacol Exp Ther (2010) 1.11
Pharmacodynamics of once- or twice-daily levofloxacin versus vancomycin, with or without rifampin, against Staphylococcus aureus in an in vitro model with infected platelet-fibrin clots. Antimicrob Agents Chemother (1996) 1.10
Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther (1993) 1.10
Pharmacokinetics of a water-soluble fullerene in rats. Antimicrob Agents Chemother (1996) 1.10
Effect of norfloxacin on theophylline pharmacokinetics at steady state. Antimicrob Agents Chemother (1988) 1.02
Impact of dosing schedule upon suppression of a retrovirus in a murine model of AIDS encephalopathy. Antimicrob Agents Chemother (1994) 1.00
Pharmacokinetics of (-)-2'-3'-dideoxy-3'-thiacytidine in woodchucks. Antimicrob Agents Chemother (1996) 0.97
Pharmacokinetics of (-)-beta-D-2-aminopurine dioxolane and (-)-beta-D-2-amino-6-chloropurine dioxolane and their antiviral metabolite (-)-beta-D-dioxolane guanine in rhesus monkeys. Antimicrob Agents Chemother (1996) 0.96
Mathematical modeling of the interrelationship of CD4 lymphocyte count and viral load changes induced by the protease inhibitor indinavir. Antimicrob Agents Chemother (1998) 0.96
Multiple-dose pharmacokinetics of oral zidovudine in hemophilia patients with human immunodeficiency virus infection. Antimicrob Agents Chemother (1990) 0.96
Comparative study of intraperitoneal and intravenous vancomycin pharmacokinetics during continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother (1987) 0.95
Use of ciprofloxacin versus use of aminoglycosides for therapy of complicated urinary tract infection: prospective, randomized clinical and pharmacokinetic study. Antimicrob Agents Chemother (1991) 0.93
Tolerance and pharmacokinetic interactions of rifabutin and azithromycin. Antimicrob Agents Chemother (2001) 0.92
Pharmacodynamics of RP 59500 (quinupristin-dalfopristin) administered by intermittent versus continuous infusion against Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model. Antimicrob Agents Chemother (1997) 0.92
Pharmacokinetics of 2',3'-dideoxyinosine in monkeys. Antimicrob Agents Chemother (1991) 0.91
Quantitative relationships between zidovudine exposure and efficacy and toxicity. Antimicrob Agents Chemother (1994) 0.90
Unusual central nervous system toxicity in a phase I study of N1N11 diethylnorspermine in patients with advanced malignancy. Invest New Drugs (1997) 0.89
A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors. Cancer Chemother Pharmacol (2011) 0.89
Modeling of the change in CD4 lymphocyte counts in patients before and after administration of the human immunodeficiency virus protease inhibitor indinavir. Antimicrob Agents Chemother (1997) 0.88
A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors. Clin Cancer Res (2010) 0.87
Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies. Invest New Drugs (2010) 0.87
Pharmacokinetics of meropenem in patients with intra-abdominal infections. Antimicrob Agents Chemother (1994) 0.86
In vitro cytotoxicity, pharmacokinetics, tissue distribution, and metabolism of small-molecule protein kinase D inhibitors, kb-NB142-70 and kb-NB165-09, in mice bearing human cancer xenografts. Cancer Chemother Pharmacol (2012) 0.85
Safety and pharmacokinetics of rimantadine small-particle aerosol. Antimicrob Agents Chemother (1990) 0.83
Intravenous and oral zidovudine pharmacokinetics and coagulation effects in asymptomatic human immunodeficiency virus-infected hemophilia patients. Antimicrob Agents Chemother (1992) 0.82
Evaluation of novel particles as pulmonary delivery systems for insulin in rats. AAPS PharmSci (2003) 0.82
A phase I trial and pharmacokinetic evaluation of CI-980 in patients with advanced solid tumors. Invest New Drugs (1997) 0.82
A multi-center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors. Pediatr Blood Cancer (2012) 0.81
Liquid chromatography-mass spectrometric assay for quantitation of the short-chain fatty acid, 2,2-dimethylbutyrate (NSC 741804), in rat plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 0.81
Pharmacokinetics of ticarcillin and clavulanic acid (timentin) in relation to renal function. Antimicrob Agents Chemother (1986) 0.81
Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma. Neuro Oncol (2008) 0.80
Pharmacokinetics, plasma protein binding and urinary excretion of N omega-nitro-L-arginine in rats. Br J Pharmacol (1994) 0.80
Pharmacokinetics and tolerability of oral rizatriptan in healthy male and female volunteers. Br J Clin Pharmacol (1999) 0.79
Pharmacokinetics and pharmacodynamics of granulocyte-macrophage colony-stimulating factor and zidovudine in patients with AIDS and severe AIDS-related complex. Antimicrob Agents Chemother (1993) 0.78
Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine. Cancer Chemother Pharmacol (2008) 0.78
Pharmacokinetics of antiviral polyoxometalates in rats. Antimicrob Agents Chemother (1994) 0.78
Ceftriaxone disposition in open-heart surgery patients. Antimicrob Agents Chemother (1989) 0.78
Peritoneal transport of cefonicid. Antimicrob Agents Chemother (1987) 0.78
Evaluation of several dosing regimens of cefepime, with various simulations of renal function, against clinical isolates of Pseudomonas aeruginosa in a pharmacodynamic infection model. Antimicrob Agents Chemother (1999) 0.77
Dose-dependent pharmacokinetics of mezlocillin in rats. Antimicrob Agents Chemother (1989) 0.76
Single dose pharmacokinetics, safety and tolerability of MK-0476, a new leukotriene D4-receptor antagonist, in healthy volunteers. Br J Clin Pharmacol (1995) 0.76
Cefonicid versus clindamycin prophylaxis for head and neck surgery in a randomized, double-blind trial, with pharmacokinetic implications. Antimicrob Agents Chemother (1991) 0.76
Searching for an optimal AUC estimation method: a never-ending task? J Pharmacokinet Pharmacodyn (2014) 0.75
Pharmacokinetics of 1-(2-fluoro-5-methyl-beta-L-arabinofuranosyl)uracil in woodchucks. Antimicrob Agents Chemother (1997) 0.75
Relationship between didanosine exposure and surrogate marker response in human immunodeficiency virus-infected outpatients. Antimicrob Agents Chemother (1998) 0.75
Pharmacokinetics of amikacin in serum and in tissue contiguous with pressure sores in humans with spinal cord injury. Antimicrob Agents Chemother (1990) 0.75
Pharmacokinetics of two multiple-dose mezlocillin regimens. Antimicrob Agents Chemother (1988) 0.75
Bioelectrical impedance modelling of gentamicin pharmacokinetic parameters. Br J Clin Pharmacol (1989) 0.75
Prenatal and postpartum pharmacokinetics of stavudine (2',3'-didehydro-3'-deoxythymidine) and didanosine (dideoxyinosine) in pigtailed macaques (Macaca nemestrina). Antimicrob Agents Chemother (1996) 0.75
Influence of subject age on the inhibition of oxidative metabolism by ciprofloxacin. Antimicrob Agents Chemother (1991) 0.75
Enhanced Dissolution and Oral Bioavailability of Piroxicam Formulations: Modulating Effect of Phospholipids. Pharmaceutics (2010) 0.75
Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm (1993) 3.96
General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn (2001) 3.21
Gentamicin disposition and tissue accumulation on multiple dosing. J Pharmacokinet Biopharm (1977) 1.90
Tissue persistence of gentamicin in man. JAMA (1977) 1.79
Ampicillin and hetacillin pharmacokinetics in normal and anephric subjects. Clin Pharmacol Ther (1973) 1.74
Prednisone side-effects and serum-protein levels. A collaborative study. Lancet (1971) 1.67
The absorption of oral micronized progesterone: the effect of food, dose proportionality, and comparison with intramuscular progesterone. Fertil Steril (1993) 1.66
Contribution of cigarette smoking to cadmium accumulation in man. Lancet (1972) 1.63
Enhanced biotransformation of theophylline in marihuana and tobacco smokers. Clin Pharmacol Ther (1978) 1.59
Effect of smoking on theophylline disposition. Clin Pharmacol Ther (1976) 1.58
Factors affecting theophylline clearances: age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates, and ethanol. J Pharm Sci (1979) 1.56
Accumulation pharmacokinetics of tobramycin. Antimicrob Agents Chemother (1978) 1.51
Effects of change in elimination on varous parameters of the two-compartment open model. J Pharm Sci (1972) 1.51
Gentamicin tissue accumulation and nephrotoxic reactions. JAMA (1978) 1.49
Renal clearance and tissue accumulation of gentamicin. Clin Pharmacol Ther (1977) 1.48
Characteristics of indirect pharmacodynamic models and applications to clinical drug responses. Br J Clin Pharmacol (1998) 1.46
Fourth-generation model for corticosteroid pharmacodynamics: a model for methylprednisolone effects on receptor/gene-mediated glucocorticoid receptor down-regulation and tyrosine aminotransferase induction in rat liver. J Pharmacokinet Biopharm (1998) 1.43
Characterization of dexamethasone binding in normal and uremic human serum. DICP (1990) 1.43
Development of translational pharmacokinetic-pharmacodynamic models. Clin Pharmacol Ther (2008) 1.42
Theophylline disposition in obesity. Clin Pharmacol Ther (1978) 1.42
Characterization of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm (1996) 1.38
Pharmacodynamic modeling of time-dependent transduction systems. Clin Pharmacol Ther (2001) 1.38
Comparison of ampicillin and hetacillin pharmacokinetics in man. J Pharm Sci (1973) 1.35
Theophylline secretion into breast milk. Pediatrics (1976) 1.35
Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena. J Pharm Sci (1998) 1.34
Theophylline pharmacokinetics in premature infants with apnea. J Pediatr (1976) 1.34
Pharmacokinetics and pharmacodynamic modeling of direct suppression effects of methylprednisolone on serum cortisol and blood histamine in human subjects. Clin Pharmacol Ther (1989) 1.32
Cadmium accumulation im man: influence of smoking, occupation, alcoholic habit and disease. J Chronic Dis (1972) 1.27
Pharmacokinetic/Pharmacodynamic models for corticosteroid receptor down-regulation and glutamine synthetase induction in rat skeletal muscle by a Receptor/Gene-mediated mechanism. J Pharmacol Exp Ther (1999) 1.27
Transit compartments versus gamma distribution function to model signal transduction processes in pharmacodynamics. J Pharm Sci (1998) 1.26
Influence of cigarette smoking on drug metabolism in man. Drug Metab Rev (1979) 1.23
Analysis of methylprednisolone, methylprednisone and corticosterone for assessment of methylprednisolone disposition in the rat. J Chromatogr (1988) 1.22
Plasma and tissue protein binding of drugs in pharmacokinetics. Drug Metab Rev (1976) 1.22
Mathematical modeling of circadian cortisol concentrations using indirect response models: comparison of several methods. J Pharmacokinet Biopharm (1999) 1.22
Urinary casts as an indicator of renal tubular damage in patients receiving aminoglycosides. Antimicrob Agents Chemother (1979) 1.21
Pharmacodynamics of chemotherapeutic effects: dose-time-response relationships for phase-nonspecific agents. J Pharm Sci (1971) 1.19
Fluid shifts and other factors affecting plasma protein binding of prednisolone by equilibrium dialysis. J Pharm Sci (1984) 1.18
Ocular absorption of topically applied FK506 from liposomal and oil formulations in the rabbit eye. Invest Ophthalmol Vis Sci (1993) 1.17
Dose-dependence and repeated-dose studies for receptor/gene-mediated pharmacodynamics of methylprednisolone on glucocorticoid receptor down-regulation and tyrosine aminotransferase induction in rat liver. J Pharmacokinet Biopharm (1998) 1.17
Basic pharmacodynamic models for agents that alter production of natural cells. J Pharmacokinet Biopharm (1999) 1.17
Role of tobacco smoking in pharmacokinetics. J Pharmacokinet Biopharm (1978) 1.16
Pharmacokinetics of aztreonam in patients with gram-negative infections. Antimicrob Agents Chemother (1985) 1.15
Digoxin pharmacokinetics: role of renal failure in dosage regimen design. Clin Pharmacol Ther (1975) 1.11
Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther (1993) 1.10
Pharmacokinetics of methicillin in patients with cystic fibrosis. J Infect Dis (1977) 1.10
Enhanced renal excretion of dicloxacillin in patients with cystic fibrosis. Pediatrics (1975) 1.09
Fluorometric analysis of ampicillin in biological fluids. J Pharm Sci (1971) 1.09
Receptor-mediated pharmacodynamics of prednisolone in the rat. J Pharmacokinet Biopharm (1986) 1.09
Algorithm for application of Fourier analysis for biorhythmic baselines of pharmacodynamic indirect response models. Chronobiol Int (2000) 1.07
Intravenous theophylline therapy: nomogram guidelines. Ann Intern Med (1977) 1.07
Precipitation of diazepam from intravenous preparations. JAMA (1973) 1.07
Pharmacokinetics of theophylline in hepatic disease. Chest (1978) 1.07
Pharmacoimmunodynamics of methylprednisolone: trafficking of helper T lymphocytes. J Pharmacokinet Biopharm (1992) 1.07
Early detection of aminoglycoside nephrotoxicity with urinary beta-2-microglobulin. J Med (1978) 1.05
Dose-dependent pharmacokinetics of mezlocillin in relation to renal impairment. Antimicrob Agents Chemother (1982) 1.05
Corticosteroid analysis in biological fluids by high-performance liquid chromatography. J Chromatogr (1979) 1.04
Pharmacokinetics of single and multiple doses of ethinyl estradiol and levonorgestrel in relation to smoking. Clin Pharmacol Ther (1988) 1.04
Dose dependent pharmacokinetics of prednisone and prednisolone in man. J Pharmacokinet Biopharm (1981) 1.03
Two-compartment basophil cell trafficking model for methylprednisolone pharmacodynamics. J Pharmacokinet Biopharm (1991) 1.03
Pharmacodynamic model for joint exogenous and endogenous corticosteroid suppression of lymphocyte trafficking. J Pharmacokinet Biopharm (1994) 1.02
Clinical pharmacokinetics and pharmacodynamics of a new squalene synthase inhibitor, BMS-188494, in healthy volunteers. J Clin Pharmacol (1998) 1.01
Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. J Clin Pharmacol (1992) 1.00
Nonlinear assessment of phenytoin bioavailability. J Pharmacokinet Biopharm (1976) 0.99
Active metabolites of imipramine and desipramine in man. Clin Pharmacol Ther (1982) 0.99
Pharmacokinetics of cyclophosphamide in man. Br J Pharmacol (1971) 0.99
Role of baseline parameters in determining indirect pharmacodynamic responses. J Pharm Sci (1999) 0.99
Molar quantification of specific messenger ribonucleic acid expression in northern hybridization using cRNA standards. Anal Biochem (1993) 0.98
Pharmacokinetics of methylprednisolone sodium succinate and methylprednisolone in patients undergoing cardiopulmonary bypass. Pharmacotherapy (1990) 0.98
Pharmacokinetics of digoxin in normal subjects after intravenous bolus and infusion doses. J Pharmacokinet Biopharm (1975) 0.98
Population pharmacokinetics of sirolimus in kidney transplant patients. Clin Pharmacol Ther (1997) 0.98
Prednisolone disposition and protein binding in oral contraceptive users. J Clin Endocrinol Metab (1983) 0.97
Modeling of dose-response-time data: four examples of estimating the turnover parameters and generating kinetic functions from response profiles. Biopharm Drug Dispos (2000) 0.97
Pharmacokinetics of antibiotic absorption in coeliac disease. J Antimicrob Chemother (1976) 0.97
Corticosteroid pharmacodynamic modeling: osteocalcin suppression by prednisolone. Pharm Res (1992) 0.97
Monitoring prednisone and prednisolone. Ther Drug Monit (1980) 0.97
Comparative tissue accumulation of gentamicin and tobramycin in patients. J Antimicrob Chemother (1978) 0.96
Estimation of oral bioavailability of a long half-life drug in healthy subjects. Pharm Res (1998) 0.96
Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion. Clin Pharmacol Ther (1986) 0.96
Third-generation model for corticosteroid pharmacodynamics: roles of glucocorticoid receptor mRNA and tyrosine aminotransferase mRNA in rat liver. J Pharmacokinet Biopharm (1995) 0.96
Species- and gender-related differences in cyclosporine/prednisolone/sirolimus interactions in whole blood lymphocyte proliferation assays. J Pharmacol Exp Ther (1998) 0.95
Dose-dependent disposition of oral propranolol in normal subjects. Biopharm Drug Dispos (1981) 0.95
Pharmacokinetics and pharmacodynamics of methylprednisolone in obesity. Clin Pharmacol Ther (1991) 0.95
Estimation of gastric residence time of the Heidelberg capsule in humans: effect of varying food composition. Gastroenterology (1985) 0.95
Pharmacokinetics in the infant. Environ Health Perspect (1994) 0.95
Partial pharmacodynamic model for the circadian-episodic secretion of cortisol in man. J Clin Endocrinol Metab (1975) 0.95
Amrinone in the treatment of chronic cardiac failure. J Am Coll Cardiol (1984) 0.95
Dosage regimen design. Pharmacol Ther (1982) 0.95
Prednisolone pharmacokinetics and pharmacodynamics in relation to sex and race. J Clin Pharmacol (2001) 0.94
Prednisolone binding to albumin and transcortin in the presence of cortisol. Biochem Pharmacol (1982) 0.94
Cimetidine does not alter morphine disposition in man. Br J Clin Pharmacol (1982) 0.94
High-performance liquid chromatographic assay for imipramine, desipramine, and their 2-hydroxylated metabolites. J Pharm Sci (1979) 0.94
Vancomycin pharmacokinetics in infants: relationships to indices of maturation. Pediatr Infect Dis (1986) 0.94
Developing compliance instructions for drug labeling. Clin Pharmacol Ther (2000) 0.94
Pharmacokinetic design of digoxin dosage regimens in relation to renal function. J Clin Pharmacol (1974) 0.94
Gentamicin persistence in the body. Lancet (1977) 0.94
Myocardial distribution of digoxin and renal function. Clin Pharmacol Ther (1974) 0.94
Modeling and allometric scaling of s(+)-ketoprofen pharmacokinetics and pharmacodynamics: a retrospective analysis. J Vet Pharmacol Ther (2004) 0.93
Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone. Clin Pharmacol Ther (1991) 0.92
Phenobarbital effects on cyclophosphamide pharmacokinetics in man. Cancer Res (1972) 0.92